“… [30] Due to the shear infinite scaffold and building block diversity applicable in MCRs, combined with the high throughput miniaturized synthesis format, many more structural opportunities can be realized. [31] With continuing technological advances in speed and scale of chemical synthesis[ 14a , 14b , 14c , 14d , 14f , 32 ] and macromolecular crystallography,[ 29a , 33 ] it is conceivable that a seamless process of in situ HT synthesis and HT PX can be performed in a cyclic fashion to truly guide compound optimization and complement the “design‐make‐test‐analyze” cycle (DMTA) in drug discovery. Assuming sufficient access to a synchrotron beamline and optimization of all working blocks, a cycle time of 1–2 weeks seems feasible which is comparable to current cycle times in the DMTA cycle but without crystallographic information.…”